12 million dollars has been invested in Israeli researchers who are racing against the clock to get their COVID-19 vaccine into human trials by summer 2020.
The MIGAL Galile Research Institute is situated in Kiryat Shmona, which is in northern Israel. Their researchers have developed a vaccine for the corona virus that affects poultry and for the past four years they have been researching another strain of the corona virus that causes infectious bronchitis. They plan to experiment on rodents in May 2020 and then they plan to start a six-month program of human trials by summer 2020.
A US patent has been awarded to an Israeli scientist at Tel Aviv University who has developed a patent for technology that could help develop a vaccine which targets the viruses RBM ( Receptor Binding Motif ), then binds to it and infects the targeted cell.
On the international front, five human trials have commenced. Germany and the UK are both investing in this crucial effort.
“In the long run, the best way to defeat the corona virus is through a vaccine”, claimed UK Health Minister Matt Hancock, “this is a new disease, an uncertain science.”
The UK is at the forefront of the global effort and the country has invested the most money into a global search for a vaccine. Two of the leading vaccine developments are taking place in the UK, at Oxford and at Imperial and both of these promising projects are making rapid progress. They have the full support of UK Health Minister Matt Hancock, who has told the scientists leading the projects that he will do everything in his power to support him. Without a doubt, the international race has started with human clinical trials and there is great anticipation and hope to find a vaccine to end this worldwide pandemic.